'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Biocon has increased 12.76% to Rs 4417 crore. Sales of Generics segment has gone up 45.81% to Rs 1,047.50 crore (accounting for 23.13% of total sales). Sales of Biosimilars segment has gone up 4.48% to Rs 2,463.40 crore (accounting for 54.39% of total sales). Sales of Research service segment has gone up 11.03% to Rs 1,018.00 crore (accounting for 22.48% of total sales). Inter-segment sales rose Rs 76.00 crore to Rs 111.90 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 31.71% to Rs 460.60 crore. PBIT of Generics segment rose 258.73% to Rs 180.80 crore (accounting for 39.25% of total PBIT). PBIT of Biosimilars segment fell 56.48% to Rs 39.30 crore (accounting for 8.53% of total PBIT). PBIT of Resear...
Pleaselogin & subscribe to view the full report.
More Reports
-
(11-May-2025)
ABB India
Sales up 3%, net up 3%
-
(10-May-2025)
Dr Reddys Laboratories
NP surged 21.64%
-
(10-May-2025)
Bank of India
Healthy loan growth, other income jumps boosting bottom-line
-
(10-May-2025)
Voltas
Net jumps 107% driven by unitary cooling products
|
|